Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Lung Neoplasms 1

Interventions

Docetaxel 6Erlotinib Hydrochloride 5Cetuximab 5Magnetic Resonance Spectroscopy 4Radiotherapy 3Cisplatin 3Biopsy 3Vorinostat 2Trastuzumab 2Taxes 2Surgical Procedures, Operative 2Specimen Handling 2SS1(dsFv)PE38 2Radiation 2Paclitaxel 2Immunohistochemistry 2Hydroxyurea 2Fluorouracil 2Fluorodeoxyglucose F18 2Filgrastim 2Everolimus 2Carboplatin 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1trastuzumab deruxtecan 1tipifarnib 1tanespimycin 1talactoferrin alfa 1sargramostim 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Salivary Gland Neoplasms × talactoferrin alfa × Clear all
NCT01528137 2016-08-02

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

Stanford University

Phase 1 Terminated
4 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡